公募基金二季报陆续出炉，明星基金最新调仓动向浮出水面。 继一季度大手笔买入寒武纪后，傅鹏博二季度盯上了新易盛，二季度末持有730.86万股，持仓市值达9.28亿元，新进其第六大重仓股。 光模块龙头新易盛自2023年以来股价涨幅1502.9%，涨幅位居全市场第二。 新易盛发布2025年半年度业绩预告，预计实现盈利37-42亿元，同比增长327.7%-385.5%，单Q2实现盈利21.27-26.27亿元，中值为23.77亿元，同比增长 339.4%，环比Q1增长51.1%；公司业绩暴增主要受益于人工智能算力相关投资持续增长，产品结构优化，高速率产品需求持续增加。 1 傅鹏博、赵枫最新持仓动向来了 傅鹏博旗下基金最新前十大重仓股依次为：胜宏科技、腾讯控股、宁德时代、中国移动、立讯精密、新易盛、寒武纪、巨星科技、三诺生物、迈为股份。 较一季度末，二季度傅鹏博新进CPO龙头新易盛，油气开采股广汇能源则退出十大重仓股；二季度减持胜宏科技、腾讯控股、宁德时代、中国移动、三诺 生物、迈为股份；增持立讯精密、寒武纪、巨星科技。 | 证券代码 | 证券简称 | 持仓市值(亿元) | 持股数量(万股) | 占股票市值比(%) | ...

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 0.56% on July 18, with a trading volume of 2.25 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of July 17, 2024, the fund's latest share count was 2.025 billion, with a total size of 3.63 billion yuan, reflecting an increase of 412.28% in shares and 860.92% in size since December 31, 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 79.25% during the management period [2] - The top holdings of the fund include Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant weightings such as 9.52% for Innovent Biologics and 9.47% for WuXi Biologics [2] - The fund's trading liquidity is strong, with a cumulative trading amount of 40.368 billion yuan over the last 20 trading days, averaging 2.018 billion yuan per day [1][2]

（原标题："沸腾"！又有两只，暴涨100%！） 【导读】又有两只基金业绩翻倍，年内"翻倍基"增至4只 中国基金报记者 张燕北 "翻倍基"又增加两只！ 创新药板块爆发，相关基金业绩上涨。截至7月17日，中银港股通医药A、永赢医药创新智选A年内单位 净值涨幅超100%，分别为年内第三只和第四只"翻倍基"。 受访基金经理表示，中期看好创新药板块的景气度。对于绝大部分中国创新药企业而言，能否进入新药 市场空间最大的欧美医药工业体系或是决定未来胜负的关键。 今年以来，重仓创新药的基金业绩领跑全市场。 除了上述四只"翻倍基"之外，截至7月17日，共计20只基金（仅统计主代码）年内单位净值涨幅超过 80%，绝大多数为聚焦创新药行业的主动或被动产品。 年内再添两只"翻倍基" 7月17日，创新药概念股强势爆发。当日，A股创新药板块指数涨幅超过3%，近20只相关概念股涨停或 涨幅超过10%；港股创新药多股创新高。 受此带动，一批医药主题基金当日净值大涨，助推年内业绩走高。截至7月17日收盘，中银港股通医药 A年内单位净值增长率达103.61%，永赢医药创新智选A涨幅达102.12%，成功跻身"翻倍基"阵营。 此前，汇添富香港优势 ...

7月17日，创新药概念股强势爆发。当日，A股创新药板块指数涨幅超过3%，近20只相关概念股涨停或涨幅超过10%；港股创新药多股创 新高。 【导读】又有两只基金业绩翻倍，年内"翻倍基"增至4只 中国基金报记者 张燕北 "翻倍基"又增加两只！ 创新药板块爆发，相关基金业绩上涨。截至7月17日， 中银港股通医药A、永赢医药创新智选A 年内单位净值涨幅超100%，分别为年内第 三只和第四只"翻倍基"。 受访基金经理表示，中期看好创新药板块的景气度。对于绝大部分中国创新药企业而言，能否进入新药市场空间最大的欧美医药工业体系 或是决定未来胜负的关键。 年内再添两只"翻倍基" 受此带动，一批医药主题基金当日净值大涨，助推年内业绩走高。截至7月17日收盘， 中银港股通医药A年内单位净值增长率达 103.61%，永赢医药创新智选A涨幅达102.12%，成功跻身"翻倍基"阵营。 除了上述四只"翻倍基"之外，截至7月17日，共计20只基金（仅统计主代码）年内单位净值涨幅超过80%，绝大多数为聚焦创新药行业的 主动或被动产品。 主动产品中，有四只基金年内单位净值涨幅超90%，年内业绩也有望翻倍，分别为华安医药生物（96.52%），中 ...

Core Views - The report indicates that the A-share market is experiencing a structural rally, with a focus on sectors with solid earnings support, particularly in innovative pharmaceuticals and technology sectors like robotics and CPO [2][11] - The upcoming important meeting is expected to emphasize macroeconomic policy adjustments, with potential increases in funding for infrastructure and support for strategic emerging industries such as AI and semiconductors [3][12] Market Overview - On Thursday, the three major indices in the A-share market collectively rose, with the Shenzhen Composite Index and the ChiNext Index showing stronger performance, while financial stocks weighed on the Shanghai Composite Index [5][11] - The market sentiment remains active, with a total trading volume of 15,394 billion, and the Shanghai Composite Index closing at 3,516.83 points, up 0.37% [6] Sector Analysis - The pharmaceutical sector saw significant gains, driven by supportive policies for innovative drugs and a favorable environment for commercialization, with expectations for continued growth in the second half of 2025 [7][11] - The optical communication module and CPO sectors are also highlighted as having strong growth potential, supported by advancements in AI computing and data center upgrades [8][11] - The aerospace and defense sector is expected to remain attractive, with government support for modernization and increased defense budgets, alongside geopolitical tensions that may act as catalysts for growth [9][10] Investment Opportunities - Investors are advised to focus on several key areas for potential investment: 1. Technology innovation sectors such as robotics, AI, and digital economy [4][13] 2. Industries benefiting from de-involution, including renewable energy and new energy vehicles [4][13] 3. Areas related to consumption upgrades and policy benefits, such as innovative pharmaceuticals and smart home devices [4][13] 4. Stocks with expected strong mid-year performance, although the intensity of speculation may decrease as earnings forecasts conclude [4][13]

【导读】狂买这些股， 又一批绩优基金经理二季报披露！ 中国基金报记者 曹雯璟 伴随基金二季报密集披露，绩优基金经理的最新持股变动、投资策略，以及对下半年的布局思路浮出水面。 根据二季报，该基金重点布局制造业、新能源、新技术等。具体来看，与一季度相比，五洲新春、汉威科技分别遭减仓93.11万股、21万 股，肇民科技、隆盛科技、北特科技、祥鑫科技、浙江荣泰、斯菱股份等新晋十大重仓股。 | 排名 | 证券代码 | 证券名称 | 持仓数量 | 持仓变动 | 持仓变动幅度 | 持仓市值 | 持仓占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 300953.SZ | 震裕科技 | 547.01万股 | 216.8万股 | 65.65% | 5.54亿元 | 5.10% | | 2 | 002779.SZ | 中坚科技 | 611.26万股 | 195.1万股 | 46.88% | 4.6 乙元 | 4.24% | | 3 | 300007.SZ | 汉威科技 | 1125.03万股 | -21万股 | -1.83% | 4.57亿元 | 4.20% ...

Core Viewpoint - The innovative drug industry continues to strengthen in Q2, significantly outperforming similar risk assets like AI and robotics sectors, attracting high market attention [1][2]. Policy Factors - The National Medical Insurance Administration (NMI) encourages innovation, leading to favorable policies for innovative drugs and a notable acceleration in domestic approvals [2]. - The introduction of a multi-layered insurance payment system is expected to enhance the market for innovative drugs, transitioning from a reliance on basic medical insurance to a dual-driven model of commercial and basic insurance [4]. Performance Factors - Many large innovative drug companies reported profits or are on the verge of profitability in their Q1 reports, boosting market confidence in the sector [2]. - The innovative drug sector has seen a significant increase in the number and value of outbound deals, with Chinese innovative drugs accounting for over half of global transactions [2]. Market Outlook - The period from 2025 to 2028 is anticipated to be crucial for Chinese innovative drug companies as they collectively enter a profitability phase, marking a potential turning point for the sector [3]. - 2025 is projected to be a pivotal year for revenue growth, with around 80% of A-share and Hong Kong-listed innovative drug companies expected to see a surge in product revenues [3]. Investment Strategy - The investment strategy focuses on identifying high-quality companies with favorable valuation through a multi-dimensional comparison of business models, competitiveness, and performance [2]. - The management of the Ping An Medical Health Mixed Securities Investment Fund has achieved a remarkable performance of 57.41% in the first half of the year, with the net value recently surpassing its previous peak in 2021 [1][5].

Core Viewpoint - Anker Innovations is exploring equity financing in the Hong Kong capital market, reflecting a growing trend of A-share companies listing in Hong Kong, with 10 companies having done so by July 17 this year [1] Group 1: A-share Companies Listing in Hong Kong - There has been a surge in A-share companies listing in Hong Kong, with 41 companies currently processing their listing applications as of mid-July [4] - The increase in A-share companies seeking to list in Hong Kong is attributed to policy support and the need for companies to expand their financing channels and international presence [4][6] - The Hong Kong IPO market has seen significant activity, with the total fundraising amount leading globally in the first half of the year [4] Group 2: Characteristics of Newly Listed A+H Companies - The newly listed A+H companies in Hong Kong this year are characterized by high market capitalization, with 9 out of 10 having a market value exceeding 10 billion yuan, and 5 exceeding 100 billion yuan [7] - These companies have demonstrated strong dividend capabilities and a focus on technology, enhancing their influence on the Hong Kong market [7] - A significant portion of the A+H companies are state-owned enterprises, with 68.13% of the 160 A+H companies being state-owned as of July 17 [7] Group 3: AH Share Premium Trends - The AH share premium has been on a downward trend, with 96.88% of A+H companies showing a premium of A-shares over H-shares as of July 17 [8] - The Hang Seng Shanghai-Shenzhen-Hong Kong Stock Connect AH share premium index was reported at 127.65, indicating that A-shares are, on average, 27% higher than H-shares [8] - The decline in AH share premium is attributed to differences in investor structure and trading mechanisms between A-shares and H-shares [8][9] Group 4: Future Outlook - It is anticipated that the trend of A-share companies listing in Hong Kong will continue over the next 2 to 3 years, supported by ongoing regulatory optimizations and market synergies [5][6] - The AH share premium is expected to continue narrowing, with factors such as increased southbound capital inflow and improved market conditions contributing to this trend [9]

Group 1 - The market shows a structural opportunity with indices rising due to strong performance in select sectors, while over 3000 stocks are experiencing adjustments [1][4] - The rare earth sector is notably strong, with companies like Jiu Wu Gao Ke hitting the daily limit up, supported by supply-demand dynamics and policy focus, alongside increasing demand from the new energy and military sectors [3][4] - The lithium mining sector is also gaining traction, with companies like Fu Miao Technology reaching the daily limit up, driven by a recovery in the new energy supply chain and stable lithium prices [3][4] Group 2 - The military industry is active, with Tian Qin Equipment rising over 12%, reflecting its connection to geopolitical and policy factors, although it may experience volatility [3][4] - Some sectors, such as innovative pharmaceuticals and photovoltaics, are facing declines, indicating a normal market rotation as funds shift focus [3][4] - The overall market dynamics suggest that while some sectors are performing well, others are consolidating, and investors should assess the fundamental support of their holdings [4]

Market Overview - The three major A-share indices experienced fluctuations, with the Shanghai Composite Index rising by 0.34%, the Shenzhen Component Index increasing by 0.30%, and the ChiNext Index up by 0.26%. The North China 50 Index fell by 0.48%. The total trading volume in the Shanghai and Shenzhen markets reached 1,029.3 billion yuan, an increase of 118.3 billion yuan compared to the previous day. Over 3,000 stocks in the market declined [1]. Sector Performance - The rare earth, lithium mining, and military industry sectors saw gains, while the innovative drug and photovoltaic sectors underwent adjustments. The rare earth sector experienced a significant rise, with stocks like Jiuwu High-Tech (300631) hitting the daily limit, and North Rare Earth (600111) reaching a three-year high. The lithium mining sector remained strong, with stocks such as Fumiao Technology and Shengxin Lithium Energy (002240) also hitting the daily limit. The military sector saw Tianqin Equipment (300922) rise over 12%. In contrast, the innovative drug sector faced fluctuations, with stocks like Guangsheng Tang (300436) and Zhijiang Biology dropping over 5%. The photovoltaic sector adjusted, with stocks like Yamaton (002623) falling over 8% [2]. Hot Stocks - The strongest stocks included Upwind New Materials, which achieved an 8-day consecutive limit-up streak [3]. - Other notable stocks with consecutive limit-ups included Haixing Co., Ltd. (603115) with a 3-day streak, and several others with 2-day streaks [4]. Sector Trends - The energy-saving and environmental protection sector led with 8 stocks hitting the daily limit, including Upwind New Materials and Beihua Co., Ltd. [5]. - The robotics concept sector also had 8 stocks hitting the daily limit, with Upwind New Materials and Construction Industry leading [6]. - The "specialized, refined, and innovative" sector saw 8 stocks hitting the daily limit, with Haixing Co., Ltd. and Beihua Co., Ltd. being notable mentions [7]. Emerging Technologies - In the brain-computer interface sector, companies like Yuke Technology and Entropy Technology are involved, following a breakthrough in clinical trials that could benefit patients with speech impairments [10]. - The AI agent sector is gaining attention with companies like Century Tianhong and Yanhua Intelligent, following the release of OpenAI's ChatGPT Agent, which can perform complex tasks [11]. - The silicon energy sector is experiencing significant changes, with the main contract for polysilicon futures rising by 7.49% to 45,700 yuan/ton, marking a new high. The price increase is driven by rising upstream silicon material prices and changes in the profit distribution within the photovoltaic industry [12][13].